相关实验视频
Updated: Jun 28, 2025

13:13
Biochemical Measurement of Neonatal Hypoxia
Published on: August 24, 2011
14.1K
新生儿低血糖症 新生儿低血糖症
Jane E Harding1, Jane M Alsweiler2,3, Taygen E Edwards1
1Liggins Institute, University of Auckland, Auckland, New Zealand.
BMJ medicine
|April 15, 2024
概括
新生儿低血糖症,或新生儿低血糖,是由于延迟的代谢变化,常见的. 早期检测和治疗对于预防潜在的脑损伤至关重要,尽管最佳的管理策略需要进一步研究.
科学领域:
- 新生儿医学 新生儿医学
- 儿科内分泌学 儿科内分泌学
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 新生儿低血糖是由于出生后代谢过渡延迟而导致的常见疾病.
- 葡萄糖是大脑的主要能量基质,严重的低血糖会导致神经糖分和不可逆转的脑损伤.
- 建议对有风险的婴儿进行例行查和及时治疗.
研究的目的:
- 审查当前对新生儿低血糖症病理生理学的理解.
- 检查关于新生儿低血糖的诊断,管理和结果的最新证据.
- 确定该领域的研究重点.
主要方法:
- 关于当前理解和最近证据的文献综述.
- 对诊断值和监测策略的分析.
- 评估治疗方式,包括食,口腔乳糖凝和静脉注射乳糖.
- 对患有轻度低血糖症的婴儿发育结果的评估.
主要成果:
- 尽管有建议,但支持许多管理方面,包括诊断值和最佳监测的强有力的证据是有限的.
- 虽然最初的治疗包括增加食,口腔乳糖凝或静脉注射乳糖,但它们的有效性和最佳使用情况各不相同.
- 患轻度低血糖症的风险婴儿可能会经历更糟糕的发育结果,尽管根本原因尚未完全理解.
结论:
- 进一步的研究是必不可少的,以建立基于证据的指导方针,用于新生儿低血糖的诊断和管理.
- 澄清即使是轻度低血糖症的长期神经发育影响至关重要.
- 优化治疗策略和监测协议将改善受影响新生儿的治疗结果.
相关概念视频
Hypoglycemia and Glucagon
257
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
257
Pathophysiology of Diabetes
924
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
924
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Glucose Transporters
22.7K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.7K
Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154

